Venture capital investments dive in the first quarter

Before you go, we thought you'd like these...
Before you go close icon

The first three months of 2009 were absolutely brutal for venture capital, with clean energy leading the way with a decline of 87 percent compared to the same period in 2008.

Overall, United States venture capital investments fell 61 percent to $3 billion in the first quarter -- the lowest level in 12 years, according to the National Venture Capital Association.

The average venture capital investment also fell from $7.8 million in the first quarter of 2008 to just $5.5 million.

With the IPO market similarly in the toilet, investors are seeing little hope of the short-term windfall that seemed so easy a few years ago. Without a ready and willing stock market to dump speculative investments on, investors are forced to continue feeding start-ups, hoping that they'll generate income at some point in the distant future.

With speculative ventures like clean technology, investors just weren't willing to tie up funds without a visible exit strategy.

Some investors are pointing to the well-received IPO of Rosetta Stone as a sign of thawing in the IPO market that will quickly lead to more aggressive venture capital investing -- but I think it's a mistake to put too much faith in a multi-billion dollar trend developing from a single IPO of a well-established brand.

Rosetta Stone has a product and delivered net income of $13.9 million on revenue of $209 million in 2008 -- a level of success that most IPOs don't have in a more normal market. I'd say that Rosetta Stone is more likely to be an anomaly than a sign of things to come.

Venture capital investments will turn around at some point, and the stimulus package will probably be a large driver of clean energy investment until that happens.

Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners